Immunology Board for Transplantation And Cell-based Therapeutics (Immuno_TACT)

To initiate global networking of Immuno-TACT through web-based advanced communication networks.

Learn more →

از آنجائیکه برخی مطالعات نشان داده اند که در بیماران مبتلا به دیابت نوع یک و مالتیپل اسکلروزیس، واکسن BCG ممکن است اثرات درمانی داشته باشد، انجام کارآزمایی های بالینی در بیماران ایرانی می تواند نه تنها اثرات پیشگیرانه واکسن بر علیه COVID-19 بسنجد بلکه اثرات درمانی این واکسن را در درمان این دو بیماری مزمن نیز نشان دهد.

Learn more →

Lung function and the immune system are also influenced by VitD through several mechanisms, including increased natural antibiotics (Defensin and Cathelicidin) and upregulated transforming growth factor‐β. A higher IgA, Th2/Th1 ratio, and T‐regulatory cells are attributable to VitD effects on the immune cells, while these changes may also be a double‐edged sword in COVID‐19.

Learn more →

NULL

Learn more →

The most important COVID-19 diagnostic test, RT-PCR, detects the presence of the SARS-CoV-2 genome in the upper respiratory tract. Extensively performing the COVID-19 RT-PCR test is one of the key indicators of success in controlling the newly emerged pandemic. Meanwhile, according to the worldometers webpage, Iran with about 49,000 testsper million people, ranked 114thin the world(August,2020)(1).Extensive testing alone is not enough for the control of the COVID-19 pandemic; a much more important indicator called "contact tracing" and its subsequent safety measures must be accompanied to control this unbridled virus. Testing and contact tracing are the two wings of flight to get out of this crisis. If the test is performed but the patient's previous communications are not being traced and subsequent safety precautions are not being taken, we are wasting the costs of the tests. While widespread, accessible, free of charge, public, and active RT-PCR testing, is quite cost-effective if being accompanied by contact tracing of positive samples(2).

Learn more →

There is evidence of increased incidence, rapid progression, and poor prognosis of COVID‐19 in patients with underlying comorbidities such as diabetes and epilepsy. Developing effective treatment regimens for COVID‐19 patients with multiple comorbidities is crucial, as patients' past medical history is an essential contributor to possible organ injuries in COVID‐19 patients. Herein, we report a confirmed case of COVID‐19 patient with a history of multiple underlying diseases, including diabetes, epilepsy, and gout. The patient developed multiple organ failure and died a week after intensive care unit (ICU) admission. Multiple organ failure is the most common cause of death in COVID‐19 patients.

Learn more →

Introduction: Multiple sclerosis (MS) is one of the most common neurological disabling diseases in human societies with no complete cure. IFN-β has been proven to be an important advance in the MS treatment, but early identification of treatment failure is its major concern. Some researches revealed that MxA is an appropriate biomarker for predicting response to IFN-β, so we performed this study to evaluate the relationship between MxA level and response to INF- β treatment.Methods: International and internal databases were searched using “MxA”, “Myxovirus resistance protein A”, “IFN-β”, “interferon Beta”, “multiple sclerosis” and “MS keywords until October 2019. Inclusion criteria were original studies considering the MxA assays in MS patients under IFN-β therapy. Some reported cut-offs from partially the same settings (7 studies) were pooled using the weighted average. Finally, the overall statements of the included studies were compared and discussed to obtain a comprehensive conclusion about the clinical value of MxA assays in patient monitoring and designing their treatment plan. Results: A total of 456 articles were identified. The Screening was led to exclusion of 427 articles. Finally, 28 original studies met the inclusion criteria for this systematic review. Almost all studies have concluded that the MxA is significantly correlated with response to IFN-β therapy and also MxA expression is under the direct effect of Neutralizing antibody (NAb) against IFN-β. Reported cut-offs for MxA ranged from 3.3 to 6.3 NR and the weighted average of them was estimated to be 4.1 NR. Conclusion: It could be suggested that in patients under IFN-β therapy with an active disease which doesn’t fulfill the criteria for the breakthrough disease, MxA level can help to determine whether to continue the drug and follow up a patient or change the treatment regimen.

Learn more →

آگاه کردن بیماران پیوند کلیوی و کادر درمان از مسایل پوستی، منجر به ارجاع زود هنگام بیماران به متخصص مربوطه و کسب درمان‌های لازم شده و باعث افزایش طول عمر و بهبود کیفیت زندگی آن‌ها خواهد شد.

Learn more →

Due to its high occurrence and mortality rate, breast cancer has been studied from various aspects as one of the cancer field's hot topics in the last decade. Epigenetic alterations are spoused to be highly effective in breast cancer development. Enhancer of zeste homolog 2 (EZH2) is an enzymatic epi-protein that takes part in most vital cell functions by its different action modes. EZH2 is suggested to be dysregulated in specific breast cancer types, particularly in advanced stages. Mounting evidence revealed that EZH2 overexpression or dysfunction affects the pathophysiology of breast cancer. In this review, we discuss biological aspects of the EZH2 molecule with a focus on its newly identified action mechanisms. We also highlight how EZH2 plays an essential role in breast cancer initiation, progression, metastasis, and invasion, which emerged as a worthy target for treating breast cancer in different approaches.

Learn more →

Highlights • Circulating EVs in bio-fluids of glioma patients can serve as potent diagnostic biomarkers in future neurosurgical practice and can reflect tumor characteristics. • Diversity of EV isolation methods, and control group recruitment strategies results in highly heterogeneous biomarkers suggested among previous studies. • Seeking normalized protocols to generate high-yield and purified EVs for biomarker discovery purpose is attracting widespread interest to increase feasibility of introduced biomarkers for further clinical application

Learn more →

we critically discuss the current status, future perspective and challenges of dendritic cell therapy for gliomas in clinics and summarize the adjuvants and antigens used for dendritic cell therapy based on Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. We used the Cochrane Collaboration’s tool to assess the bias risk in each trial. Furthermore, we summarize the study population and setting, study blinding, comparators, dosage, treatment regimens and durations, efficacy and safety issues of the clinical trials published on DC therapy for gliomas and also report the results of our meta-analysis on safety, and clinical/immunological efficacy of dendritic cell therapy for gliomas in the past decades.

Learn more →

CD96-TIGIT axis regulates anti-tumor immune responses. Thus, the receptors within this axis are the potential candidates for hematological and solid tumors immunotherapy. Combining the inhibition of CD96-TIGIT with anti-PD-1/PD-L1 mAbs and chemotherapy drugs has shown relatively effective results in the context of preclinical studies and tumor models.

Learn more →

Glioblastoma (grade IV glioma) is the most aggressive histopathological subtype of glial tumors with inordinate microvascular proliferation as one of its key pathological features. Extensive angiogenesis in the tumor microenvironment supplies oxygen and nutrients to tumoral cells; retains their survival under hypoxic conditions; and induces an immunosuppressive microenvironment. Anti-angiogenesis therapy for high-grade gliomas has long been studied as an adjuvant immunotherapy strategy to overcome tumor growth. In the current review, we discussed the underlying molecular mechanisms contributing to glioblastoma aberrant angiogenesis. Further, we discussed clinical applications of monoclonal antibodies, tyrosine kinase inhibitors, and aptamers as three major subgroups of anti-angiogenic immunotherapeutics and their limitations. Moreover, we reviewed clinical and preclinical applications of small interfering RNAs (siRNAs) as the next-generation anti-angiogenic therapeutics and summarized their potential advantages and limitations. siRNAs may serve as next-generation anti-angiogenic therapeutics for glioma. Additionally, application of nanoparticles as a delivery vehicle could increase their selectivity and lower their off-target effects.

Learn more →

passive immunotherapy has been considered a complementary remedy and a promising way to manage COVID-19. These approaches arebased on reduced inflammation due to inhibiting cytokine storm phenomena, immunomodulation,preventing acute respiratory distress syndrome (ARDS), viral neutralization, anddecreased viral load. This article highlights passive immunotherapy and immunomodulation approaches in managing and treating COVID-19 patients and discusses relevant clinical trials (CTs).

Learn more →

In December 2019, the world witnessed the occurrence of a new coronavirus to humanity. The disease spread quickly and became known as a pandemic globally, affecting both society and the health care system, both the elderly and young groups of people, and both the men’s and women’s groups. It was a universal challenge that immediately caused a surge in scientific research. Be a part of a world rising in fighting against the pandemic, the Coronavirus Disease - COVID-19 was depicted in the early days of the pandemic, but updated by more than 200 scientists and clinicians to include many facets of this new infectious pandemic, including i, characteristics, ecology, and evolution of coronaviruses; ii, epidemiology, genetics, and pathogenesis (immune responses and oxidative stress) of the disease; iii, diagnosis, prognosis, and clinical manifestations of the disease in pediatrics, geriatrics, pregnant women, and neonates; iv, challenges of co-occurring the disease with tropical infections, cardiovascular diseases, hypertension, and cancer and to the settings of dentistry, hematology, ophthalmology, and pharmacy; v, transmission, prevention, and potential treatments, ranging from supportive ventilator support and nutrition therapy to potential virus- and host-based therapies, immune-based therapies, photobiomodulation, antiviral photodynamic therapy, and vaccines; vi, the resulting consequences on social lives, mental health, education, tourism industry and economy; and vii, multimodal approaches to solve the problem by bioinformatic methods, innovation and ingenuity, globalization, social and scientific networking, interdisciplinary approaches, and art integration. We are approaching December 2020 and the still presence of COVID-19, asking us to call it COVID (without 19).

Learn more →

ستان به عنوان یکی از اعضای بدن پستانداران از لحاظ تأمین غذای نوزادانی که به دنیا می‌آورند، مهم و از حیث کمک به ایمنی فرزندانشان بسیار حائز اهمیت است. در انسان، این عضو هم از لحاظ ساختار شخصیتی و نیز تکمیل زیبایی واجدین آن و هم از لحاظ اعمال خطرهای جانی حاصل از بیماری‌های آن، اهمیت چند جانبه دارند و از این لحاظ حفظ سلامتی و نگهداری این عضو جای شک و تردیدی باقی نمی‌گذارد. با عنایت به نقش آگاهی و دانش در پیشگیری و درمان به موقع بیماری‌ها، آگاهی بخشیدن به جامعه هدف یعنی خانم‌های سازنده نسل‌های‌آینده، نقش چشمگیری در حفظ و بقای این عزیزان ایفا می‌کند.

Learn more →

سخنرانی دکتر مهزاد اکبرپور مدیر فنی مرکز سلول درمانی و پیوند سلول های بنیادی بیمارستان دانشگاه شیکاگو

Learn more →